Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 136 publications
Real-World Effectiveness and Safety of Deucravacitinib for Adult Patients with Plaque Psoriasis: A 16-Week Multicenter Retrospective Study of Monotherapy and Combination Therapy.
Journal: Journal of cutaneous medicine and surgery
Published: June 05, 2026
Evaluation of Injection Site Pain and Adherence in Patients Transitioning from a High to Low Volume Adalimumab Formulation (AVT02, Simlandi®) Across Multiple Indications (EASE PAIN).
Journal: Rheumatology and therapy
Published: February 18, 2026
Three-Year Patient-Reported Outcomes From Bimekizumab for Plaque Psoriasis: The BE RADIANT Randomized Clinical Trial With Open-Label Extension.
Journal: JAMA dermatology
Published: February 18, 2026
Durability of Response to Icotrokinra in Adults With Moderate-to-Severe Plaque Psoriasis: One-Year Results From the Phase 3, Placebo- and Active Comparator-Controlled ICONIC-ADVANCE 1 & ICONIC-ADVANCE 2 Trials.
Journal: The British journal of dermatology
Published: January 30, 2026
Zasocitinib (TAK-279), a Highly Selective Oral TYK2 Inhibitor, Demonstrates Skin Clearance in Patients with Moderate-to-Severe Plaque Psoriasis: Post Hoc Analyses of a Randomized Phase IIb Trial.
Journal: Dermatology and therapy
Published: January 27, 2026
Real-World Effectiveness and Safety of Tildrakizumab for Plaque Psoriasis: A 3-Year International Multicenter Retrospective Study.
Journal: Dermatology and therapy
Published: November 03, 2025
Bimekizumab Efficacy in Psoriasis by Subgroups: Post Hoc Analysis of Phase 3/3b Clinical Trials.
Journal: Dermatology and therapy
Published: August 11, 2025
Drug-Induced Generalized Pustular Psoriasis: A Systematic Review.
Journal: Journal of cutaneous medicine and surgery
Published: August 11, 2025
The hf-PGA is a valid and reliable measure of hand/foot psoriasis severity in adults: results from a phase 2b clinical trial.
Journal: The Journal of dermatological treatment
Published: July 15, 2025
Once-daily oral icotrokinra versus placebo and once-daily oral deucravacitinib in participants with moderate-to-severe plaque psoriasis (ICONIC-ADVANCE 1 & 2): two phase 3, randomised, placebo-controlled and active-comparator-controlled trials.
Journal: Lancet (London, England)
Published: July 08, 2025
Disease Duration in Patients Recruited to Psoriasis Phase III Trials: A Systematic Review.
Journal: American journal of clinical dermatology
Published: June 05, 2025
Bacteriophage therapy in dermatology: A systematic review.
Journal: Journal of the European Academy of Dermatology and Venereology : JEADV
Published: May 22, 2025
Last Updated: 09/26/2026